Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Mechanism of Action of Retatrutide (Triple-Target GLP1+GIP+GCGR Agonist) Retatrutide is a new-generation triple co-agonist independently developed by Eli Lilly
GPX5 is an unusual member of the mammalian GPX family because, unlike the well-known mammalian GPX1-4, it does not contain selenosylcysteine (Secys) at its active site, but instead has cysteine residues (Cys) as its active site (Taylor et al., 2013)
In future, to better understand the possible role of altered cognition and acceptance bias in this bi-directional relationship, longitudinal studies should measure changes in effort-based decision-making over time and assess how this relates to metabolic health changes
This article is general information, not a substitute for a medical consultation
Ozempic EPAR Product Information
Drug-induced pancreatitis
